Spiking dependence of SARS‐CoV‐2 pathogenicity on TMPRSS2
Review
[키워드] Affect
affected
blocker
Cell
clinical trial
coronavirus
COVID‐19
COVID‐19
determine
difference
differential expression
Differential gene expression
discrepancy
disease
drug
Entry mechanism
enzyme
enzyme activity
ethnic group
expressed
expression
Factor
gastrointestinal tract
group
groups
highlight
host cell
host protease TMPRSS2
host susceptibility
humans
implicated
infections
inhibitor
investigated
kidney
outcome
outcomes
pathogenicity
Prostate
Region
regulated
reported
respiratory tract
SARS‐CoV‐2
SARS‐CoV‐2 infection
SARS‐CoV‐2
susceptibility
therapeutic option
TMPRSS2
TMPRSS2 blockers
TMPRSS2 inhibitors
TMPRSS2 protease
Treatment
viral entry
viral spike protein
[DOI] 10.1002/jmv.26911 PMC 바로가기 [Article Type] Review
[DOI] 10.1002/jmv.26911 PMC 바로가기 [Article Type] Review